Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer

References

• Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. Jama. 2013;309(22):2371–2381. .
   Google Scholar
• Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525–533.
   Google Scholar
• Lipshultz SE, Karnik R, Sambatakos P, et al. Anthracycline-related cardiotoxicity in childhood cancer survivors. Curr Opin Cardiol. 2014;29(1):103–112.
   Google Scholar
• Franco VI, Lipshultz SE. Cardiac complications in childhood cancer survivors treated with anthracyclines. Cardiol Young. 2015;25(Suppl 2):107–116.
   Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, editors, et al. SEER Cancer Statistics Review, 1975-2016. Bethesda (MD): National Cancer Institute [based on November 2018 SEER data submission, posted to the SEER web site, April 2019]. https://seer.cancer.gov/csr/1975_2016/.
   Google Scholar
• Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017;390(10112):2569–2582.
   Google Scholar
• Lipshultz SE, Diamond MB, Franco VI, et al. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs. 2014;16(5):373–389.
   Google Scholar
• Marcoux S, Drouin S, Laverdiere C, et al. The PETALE study: late adverse effects and biomarkers in childhood acute lymphoblastic leukemia survivors. Pediatr Blood Cancer. 2017;64(6). doi:10.1002/pbc.26361
   Google Scholar
• Chow EJ, Leger KJ, Bhatt NS, et al. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res. 2019;115(5):922–934.
   Google Scholar
• Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011;2011:942090.
   Google Scholar
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–2247.
   Google Scholar
• Hudson MM, Leisenring W, Stratton KK, et al. Increasing cardiomyopathy screening in at-risk adult survivors of pediatric malignancies: a randomized controlled trial. J clin oncol. 2014;32(35):3974–3981.
   Google Scholar
• Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808–815.
   Google Scholar
• Kremer LC, van Dalen EC, Offringa M, et al. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503–512.
   Google Scholar
• Octavia Y, Tocchetti CG, Gabrielson KL, et al. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–1225.
   Google Scholar
• Olson RD, Mushlin PS. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. Faseb J. 1990;4(13):3076–3086.
   Google Scholar
• Chow EJ, Antal Z, Constine LS, et al. New Agents, Emerging Late Effects, and the Development of Precision Survivorship. J Clin Oncol. 2018;36(21):2231–2240.
   Google Scholar
• Barry E, Alvarez JA, Scully RE, et al. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007;8(8):1039–1058.
   Google Scholar
• Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63(10):945–953.
   Google Scholar
• Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7(4):214–220.
   Google Scholar
• Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006;33(3 Suppl 8):S8–14.
   Google Scholar
• Hutchins KK, Siddeek H, Franco VI, et al. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017;83(3):455–465.
   Google Scholar
• Fornaro A, Olivotto I, Rigacci L, et al. Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience. Eur J Heart Fail. 2018;20(5):898–906.
   Google Scholar
• Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547–558.
   Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
   Google Scholar
• van Dalen EC, van der Pal HJ, Kok WE, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42(18):3191–3198.
   Google Scholar
• Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. Bmj. 2009;339:b4606.
   Google Scholar
• Dewilde S, Carroll K, Nivelle E, et al. Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective. Cost Eff Resour Alloc. 2020;18:7.
   Google Scholar
• Brown TR, Vijarnsorn C, Potts J, et al. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study. Pediatr Blood Cancer. 2013;60(5):842–848.
   Google Scholar
• Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11(7):670–678.
   Google Scholar
• Blanco JG, Sun C-L, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes–a report from the children’s oncology group. J Clin Oncol. 2012;30(13):1415–1421.
   Google Scholar
• Linschoten M, Teske AJ, Cramer MJ, et al. Chemotherapy-related cardiac dysfunction. Circ Genomic Precis Med. 2018;11(1):e001753.
   Google Scholar
• Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105–113.
   Google Scholar
• Corremans R, Adão R, De Keulenaer GW, et al. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Clin Exp Pharmacol Physiol. 2019;46(3):204–215.
   Google Scholar
• Megias-Vericat JE, Martinez-Cuadron D, Herrero MJ, et al. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia. Curr Drug Metab. 2018;19(1):55–74.
   Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
   Google Scholar
• Neudorf U, Schönecker A, Reinhardt D. Cardio-toxicity in childhood cancer survivors “Cure is not enough”. J Thorac Dis. 2018;10(Suppl 35):S4344–S50.
   Google Scholar
• Tripaydonis A, Conyers R, Elliott DA. Pediatric Anthracycline-Induced Cardiotoxicity: mechanisms, Pharmacogenomics, and Pluripotent Stem-Cell Modeling. Clin Pharmacol Ther. 2019;105(3):614–624.
   Google Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–741.
   Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18(11):1639–1642.
   Google Scholar
• Sinha BK. Free radicals in anticancer drug pharmacology. Chem Biol Interact. 1989;69(4):293–317.
   Google Scholar
• Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983;43(10):4543–4551.
   Google Scholar
• Goodman J, Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun. 1977;77(2):797–803.
   Google Scholar
• Lipshultz SE, Sambatakos P, Maguire M, et al. Cardiotoxicity and Cardioprotection in Childhood Cancer. Acta Haematol. 2014;132(3–4):391–399.
   Google Scholar
• Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. Faseb J. 2004;18(6):664–675.
   Google Scholar
• Sinha BK, Mason RP. Is metabolic activation of topoisomerase II poisons important in the mechanism of cytotoxicity? J Drug Metab Toxicol. 2015;6:3.
   Google Scholar
• Vavrova A, Jansova H, Mackova E, et al. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells. PLoS One. 2013;8(10):e76676.
   Google Scholar
• Farmakis D, Mantzourani M, Filippatos G. Anthracycline-induced cardiomyopathy: secrets and lies. Eur J Heart Fail. 2018;20(5):907–909.
   Google Scholar
• Vejpongsa P, Yeh ETH. Prevention of Anthracycline-Induced Cardiotoxicity: challenges and Opportunities. J Am Coll Cardiol. 2014;64(9):938–945.
   Google Scholar
• Stewart DJ, Grewaal D, Green RM, et al. Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues. Anticancer Res. 1993;13(6a):1945–1952.
   Google Scholar
• Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H: quinoneoxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer. 2008;112(12):2789–2795.
   Google Scholar
• Wojnowski L, Kulle B, Schirmer M, et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation. 2005;112(24):3754–3762.
   Google Scholar
• Huang K, Hu S, Sparreboom A. Drug transporters and anthracycline-induced cardiotoxicity. Pharmacogenomics. 2018;19. doi:10.2217/pgs-2018-0056.
   Google Scholar
• Zhai X, Wang H, Zhu X, et al. Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia. Arch Med Sci. 2012;8(4):659–671.
   Google Scholar
• Milosevic G, Kotur N, Krstovski N, et al. Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia. J Med Biochem. 2018;37(3):320–327.
   Google Scholar
• Hattinger CM, Biason P, Iacoboni E, et al. Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma. Oncotarget. 2016;7(38):61970–61987.
   Google Scholar
• Ansari M, Sauty G, Labuda M, et al. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2012;12(5):386–394.
   Google Scholar
• Umlauf J, Horký M. Molecular biology of doxorubicin-induced cardiomyopathy. Exp Clin Cardiol. 2002;7(1):35–39.
   Google Scholar
• Kotamraju S, Chitambar CR, Kalivendi SV, et al. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277(19):17179–17187.
   Google Scholar
• Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18.
   Google Scholar
• Hasinoff BB, Herman EH. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol. 2007;7(2):140–144.
   Google Scholar
• Hildebrandt MAT, Reyes M, Wu X, et al. Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. Sci Rep. 2017;7(1):9698.
   Google Scholar
• Krajinovic M, Elbared J, Drouin S, et al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):530–535.
   Google Scholar
• Lipshultz SE, Lipsitz SR, Kutok JL, et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013;119(19):3555–3562.
   Google Scholar
• Rajić V, Aplenc R, Debeljak M, et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009;50(10):1693–1698.
   Google Scholar
• Ruiz-Pinto S, Pita G, Patino-Garcia A, et al. Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer. Pharmacogenet Genomics. 2017;27(12):445–453.
   Google Scholar
• Sági JC, Egyed B, Kelemen A, et al. Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma. BMC Cancer. 2018;18(1):704.
   Google Scholar
• Semsei AF, Erdelyi DJ, Ungvari I, et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int. 2012;36(1):79–86. doi:10.1042/CBI20110264
   Google Scholar
• Visscher H, Rassekh SR, Sandor GS, et al. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015;16(10):1065–1076.
   Google Scholar
• Visscher H, Ross CJD, Rassekh SR, et al. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children. J clin oncol. 2012;30(13):1422–1428.
   Google Scholar
• Wang X, Liu W, Sun CL, et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children’s oncology group. J Clin Oncol. 2014;32(7):647–653.
   Google Scholar
• Wang X, Sun CL, Quinones-Lombrana A, et al. CELF4 variant and anthracycline-related cardiomyopathy: a children’s oncology group genome-wide association study. J Clin Oncol. 2016;34(8):863–870.
   Google Scholar
• Aminkeng F, Bhavsar AP, Visscher H, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47(9):1079–1084.
   Google Scholar
• Schumacher T, Benndorf RA. ABC Transport Proteins in Cardiovascular Disease-A Brief Summary. Molecules. 2017;22(4):589.
   Google Scholar
• Visscher H, Ross CJD, Rassekh SR, et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer. 2013;60(8):1375–1381.
   Google Scholar
• Flens MJ, Zaman GJ, van der Valk P, et al. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996;148(4):1237–1247.
   Google Scholar
• de Grouw EPLM, Raaijmakers MHGP, Boezeman JB, et al. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38− cells. Leukemia. 2006;20(4):750–754.
   Google Scholar
• Girardi E, Cesar-Razquin A, Lindinger S, et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat Chem Biol. 2020. doi:10.1038/s41589-020-0483-3
   Google Scholar
• César-Razquin A, Snijder B, Frappier-Brinton T, et al. A Call for Systematic Research on Solute Carriers. Cell. 2015;162(3):478–487.
   Google Scholar
• Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016;82(3):683–695.
   Google Scholar
• Vulsteke C, Pfeil AM, Maggen C, et al. Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients. Breast Cancer Res Treat. 2015;152(1):67–76.
   Google Scholar
• Reichwagen A, Ziepert M, Kreuz M, et al. Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma. Pharmacogenomics. 2015;16(4):361–372.
   Google Scholar
• Cano-Soldado P, Pastor-Anglada M. Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition. Med Res Rev. 2012;32(2):428–457.
   Google Scholar
• Mata JF, García-Manteiga JM, Lostao MP, et al. Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. Mol Pharmacol. 2001;59(6):1542–1548.
   Google Scholar
• Nagasawa K, Nagai K, Ohnishi N, et al. Contribution of specific transport systems to anthracycline transport in tumor and normal cells. Curr Drug Metab. 2001;2(4):355–366.
   Google Scholar
• Shen H, Lai Y, Rodrigues AD. Organic anion transporter 2: an enigmatic human solute carrier. Drug Metab Dispos. 2017;45(2):228–236.
   Google Scholar
• Cheng Y, Vapurcuyan A, Shahidullah M, et al. Expression of organic anion transporter 2 in the human kidney and its potential role in the tubular secretion of guanine-containing antiviral drugs. Drug Metab Dispos. 2012;40(3):617–624.
   Google Scholar
• Kobayashi Y, Ohshiro N, Sakai R, et al. Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005;57(5):573–578.
   Google Scholar
• Shibayama Y, Ushinohama K, Ikeda R, et al. Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 2006;97(11):1260–1266.
   Google Scholar
• Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J. 2010;31(14):1771–1779.
   Google Scholar
• Liu S, Wang BH, Kompa AR, et al. Antagonists of organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol. 2012;158(3):457–458.
   Google Scholar
• Bennett KM, Liu J, Hoelting C, et al. Expression and analysis of two novel rat organic cation transporter homologs, SLC22A17 and SLC22A23. Mol Cell Biochem. 2011;352(1–2):143–154.
   Google Scholar
• Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha. J Biol Chem. 2002;277(34):30559–30566.
   Google Scholar
• Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9.
   Google Scholar
• Mordente A, Meucci E, Silvestrini A, et al. New developments in anthracycline-induced cardiotoxicity. Curr Med Chem. 2009;16(13):1656–1672.
   Google Scholar
• Tesauro M, Thompson WC, Rogliani P, et al. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA. 2000;97(6):2832–2835.
   Google Scholar
• Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83(8):1033–1040.
   Google Scholar
• Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol. 2013;163(2):205–213.
   Google Scholar
• Iacobucci I, Lonetti A, Candoni A, et al. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. Pharmacogenomics J. 2013;13(4):335–341.
   Google Scholar
• Birley AJ, James MR, Dickson PA, et al. ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. Hum Mol Genet. 2009;18(8):1533–1542.
   Google Scholar
• Clerk A, Cullingford TE, Fuller SJ, et al. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol. 2007;212(2):311–322.
   Google Scholar
• Preedy VR, Patel VB, Reilly ME, et al. Oxidants, antioxidants and alcohol: implications for skeletal and cardiac muscle. Front Biosci. 1999;4:e58–66.
   Google Scholar
• Li S-Y, Ren J. Cardiac overexpression of alcohol dehydrogenase exacerbates chronic ethanol ingestion-induced myocardial dysfunction and hypertrophy: role of insulin signaling and ER stress. J Mol Cell Cardiol. 2008;44(6):992–1001.
   Google Scholar
• Ge W, Yuan M, Ceylan AF, et al. Mitochondrial aldehyde dehydrogenase protects against doxorubicin cardiotoxicity through a transient receptor potential channel vanilloid 1-mediated mechanism. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2016;1862(4):622–634.
   Google Scholar
• Chaudhary KR, Batchu SN, Seubert JM. Cytochrome P450 enzymes and the heart. IUBMB Life. 2009;61(10):954–960.
   Google Scholar
• Powell WS, Rokach J. Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid. Biochim Biophys Acta. 2015;1851(4):340–355.
   Google Scholar
• Zordoky BNM, Anwar-Mohamed A, Aboutabl ME, et al. Acute doxorubicin cardiotoxicity alters cardiac cytochrome P450 expression and arachidonic acid metabolism in rats. Toxicol Appl Pharmacol. 2010;242(1):38–46.
   Google Scholar
• Seubert JM, Zeldin DC, Nithipatikom K, et al. Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury. Prostaglandins Other Lipid Mediat. 2007;82(1–4):50–59.
   Google Scholar
• Zhang Y, El-Sikhry H, Chaudhary KR, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2009;297(1):H37–H46.
   Google Scholar
• L’Ecuyer T, Allebban Z, Thomas R, et al. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol. 2004;286(6):H2057–64.
   Google Scholar
• Emadi A, Karp JE. The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics. 2012;13(11):1257–1269.
   Google Scholar
• Windsor RE, Strauss SJ, Kallis C, et al. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study. Cancer. 2012;118(7):1856–1867.
   Google Scholar
• Waldenström A, Martinussen HJ, Gerdin B, et al. Accumulation of hyaluronan and tissue edema in experimental myocardial infarction. J Clin Invest. 1991;88(5):1622–1628.
   Google Scholar
• Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev. 2000;80(2):853–924.
   Google Scholar
• Kim J, Ogai A, Nakatani S, et al. Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. J Am Coll Cardiol. 2006;48(7):1378–1384.
   Google Scholar
• Zeng Z, Shen L, Li X, et al. Disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis. Clin Sci (Lond). 2014;127(7):435–448.
   Google Scholar
• He G-H, Cai W-K, Zhang J-B, et al. Associations of Polymorphisms in HRH2, HRH3, DAO, and HNMT Genes with Risk of Chronic Heart Failure. Biomed Res Int. 2016;2016:1208476.
   Google Scholar
• Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol. 2002;3(9):639–650.
   Google Scholar
• Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2017;13(4):270–275.
   Google Scholar
• Lemasters JJ, Theruvath TP, Zhong Z, et al. Mitochondrial calcium and the permeability transition in cell death. Biochim Biophys Acta. 2009;1787(11):1395–1401.
   Google Scholar
• Shanmughapriya S, Rajan S, Hoffman NE, et al. SPG7 Is an Essential and Conserved Component of the Mitochondrial Permeability Transition Pore. Mol Cell. 2015;60(1):47–62.
   Google Scholar
• Baines CP. The Cardiac Mitochondrion: nexus of Stress. Annu Rev Physiol. 2010;72(1):61–80.
   Google Scholar
• Hurst S, Baggett A, Csordas G, et al. SPG7 targets the m-AAA protease complex to process MCU for uniporter assembly, Ca(2+) influx, and regulation of mitochondrial permeability transition pore opening. J Biol Chem. 2019;294(28):10807–10818.
   Google Scholar
• Dolphin CT, Beckett DJ, Janmohamed A, et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primates, encodes a truncated, nonfunctional protein. J Biol Chem. 1998;273(46):30599–30607.
   Google Scholar
• Schugar RC, Brown JM. Emerging roles of flavin monooxygenase 3 in cholesterol metabolism and atherosclerosis. Curr Opin Lipidol. 2015;26(5):426–431.
   Google Scholar
• Robinson-Cohen C, Newitt R, Shen DD, et al. Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients. PloS One. 2016;11(8):e0161074–e.
   Google Scholar
• Phillips IR, Shephard EA. Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease. Xenobiotica. 2020;50(1):19–33.
   Google Scholar
• England J, Drouin S, Beaulieu P, et al. Genomic determinants of long-term cardiometabolic complications in childhood acute lymphoblastic leukemia survivors. BMC Cancer. 2017;17(1):751.
   Google Scholar
• Petrykey K, Lippe S, Robaey P, et al. Influence of genetic factors on long-term treatment related neurocognitive complications, and on anxiety and depression in survivors of childhood acute lymphoblastic leukemia: the Petale study. PLoS One. 2019;14(6):e0217314.
   Google Scholar
• Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1–2):279–284.
   Google Scholar
• Benjamini Y, Yekutieli D. Quantitative trait Loci analysis using the false discovery rate. Genetics. 2005;171(2):783–790.
   Google Scholar
• Cropp CD, Komori T, Shima JE, et al. Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008;73(4):1151–1158.
   Google Scholar
• Hediger MA, Clemencon B, Burrier RE, et al. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med. 2013;34(2–3):95–107.
   Google Scholar
• Dawson PA. Role of the intestinal bile acid transporters in bile acid and drug disposition. Handb Exp Pharmacol. 2011;2011(201):169–203.
   Google Scholar
• Balakrishnan A, Polli JE. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol Pharm. 2006;3(3):223–230.
   Google Scholar
• Klutho PJ, Dashek RJ, Song L, et al. Genetic manipulation of SPG7 or NipSnap2 does not affect mitochondrial permeability transition. Cell Death Discov. 2020;6:5.
   Google Scholar